Northern Powerhouse Premier Trade Mission
In March 2020, LightOx CEO Sam Whitehouse and Business Development Executive Amy Wright attended the…
OVERVIEW
We are developing therapeutics to target the most common oral cancer using a simple local delivery system that combines both diagnostic and therapeutic capabilities.
This approach enables early identification of oral squamous cell carcinoma and instant treatment by inducing apoptosis (natural cell death) of the selected cells and tissues with minimal damage to healthy cells.
Our therapeutics are based on the development of their patented fluorescent imaging and probe technologies.
We are offering these probes for research imaging applications through Merck and for research use as therapeutics which enable cell imaging, detection, tracking and tagging of bioactive molecules, with these tags imaged using fluorescence and/or Raman spectroscopy.
The probes are drug-like molecules, smaller than other commercially available similar products, meaning they bypass many traditional problems associated with other fluorescent bioprobes. They pass freely into cells with minimal disruption of cell activity prior to light activation, fundamentally changing the way in which these such phototherapeutic compounds can be delivered to patients.
NEWS & EVENTS
Latest News
Genesis 2019
In December 2019, LightOx’s business development executive Amy Wright attended the Genesis conference in London…
ELRIG ‘Looking Back to the Future’ Conference
Towards the end of 2019, a team of experts from LightOx attended the ELRIG “looking…
Our new technologies fundamentally change the way in which light-based therapies are delivered to the patient.
A new class of patented small molecule, fluorescent, drug-like compounds which overcome the limitations of current light-based treatments.
PHOTODYNAMIC THERAPY
Photodynamic Therapy is a treatment that uses special drugs, called photosensitising agents, along with light, to kill cancer cells.
LEARN MORE
LIGHTOX
A Unique Range of Molecular Tools for use in Imaging, Therapeutics and Assay Development.
LEARN MORE